Astrana Health (NASDAQ:ASTH) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Astrana Health (NASDAQ:ASTH) from a hold rating to a buy rating in a research note published on Saturday.

Other equities research analysts have also issued research reports about the company. Robert W. Baird set a $45.00 target price on Astrana Health in a research report on Friday, May 8th. BTIG Research lifted their price target on shares of Astrana Health from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Needham & Company LLC increased their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Truist Financial raised their price objective on Astrana Health from $38.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Finally, Weiss Ratings upgraded Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and an average target price of $48.29.

Astrana Health Price Performance

ASTH stock opened at $35.76 on Friday. The stock has a 50-day moving average price of $41.36 and a two-hundred day moving average price of $32.47. Astrana Health has a 1 year low of $18.08 and a 1 year high of $51.60. The stock has a market cap of $1.99 billion, a PE ratio of 43.61 and a beta of 0.87. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45. The company had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. Astrana Health had a return on equity of 10.43% and a net margin of 1.05%.The company’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.42 earnings per share. Equities analysts forecast that Astrana Health will post 1.18 EPS for the current fiscal year.

Institutional Trading of Astrana Health

A number of institutional investors have recently bought and sold shares of ASTH. Signaturefd LLC grew its position in shares of Astrana Health by 57.9% during the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock worth $26,000 after purchasing an additional 388 shares in the last quarter. Swiss National Bank raised its position in shares of Astrana Health by 1.2% in the third quarter. Swiss National Bank now owns 86,944 shares of the company’s stock valued at $2,465,000 after buying an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Astrana Health by 5.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock valued at $799,000 after buying an additional 1,263 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Astrana Health by 3.9% in the fourth quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock valued at $1,024,000 after buying an additional 1,550 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Astrana Health by 3.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 42,258 shares of the company’s stock valued at $1,049,000 after buying an additional 1,562 shares during the period. Institutional investors own 52.77% of the company’s stock.

Trending Headlines about Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Astrana Health reported non-GAAP earnings of $0.40 per share, up from $0.19 a year earlier and above the $0.31 consensus estimate. A separate report cited $0.80 in EPS versus a $0.34 estimate, reflecting differences between reported and adjusted measures. ASTH Q2 Earnings Top Estimates
• Positive Sentiment: Revenue continued to grow rapidly. Second-quarter revenue reached approximately $972.5 million, an increase of 48.5% year over year. Management and analysts highlighted operating leverage, technology investments and artificial intelligence initiatives as potential drivers of future profitability. ASTH Q2 Deep Dive
• Positive Sentiment: Third-quarter revenue guidance points to continued expansion. Astrana Health forecast revenue of $1.00 billion to $1.03 billion for the third quarter, supporting expectations for sustained growth. ASTH Third-Quarter Revenue Guidance
• Neutral Sentiment: Full-year revenue guidance was maintained at $3.8 billion to $4.1 billion. The midpoint is broadly consistent with the roughly $4.0 billion analyst consensus, suggesting no major change to the outlook. Astrana Health Second-Quarter Results
• Negative Sentiment: Quarterly revenue was below expectations. Revenue of approximately $972.5 million trailed the $985.6 million consensus estimate. Astrana Health also continues to operate with a thin net margin, making execution and cost control important to the stock’s valuation. Astrana Health Earnings Report

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.